A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease.

Trial Profile

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2013

At a glance

  • Drugs Atopaxar (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms J-LANCELOT
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 27 Mar 2012 Biomarker results presented at the 61st Annual Scientific Session of the American College of Cardiology.
    • 30 Aug 2010 Results have been published in the European Heart Journal.
    • 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top